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Abstract. The poor performance of toxin enzyme immunoassay (EIA) 
for laboratory testing for Clostridium difficile (C. difficile) infection (CDI) 
is well acknowledged. Guidelines published in recent years state that 
testing solely with EIA for detecting toxins A and B is sub-optimal. As 
a consequence, clinicians may lose confidence in the test and submit 
multiple samples to offset the poor sensitivity of the toxin EIA. This 
leads to waste of laboratory resources and is discouraged by recent 
guidelines. 2,489 requests for toxin EIA submitted during one year at 
a state general hospital in Malta were reviewed to assess the utility of 
repeat stool testing for C. difficile toxin detection using toxin EIA and 
also to gather data on the extent of repeat samples within 28 days of 
a positive test. There were a total of 1,970 diarrhoeal episodes, from 
which a total of 302 cases (15.3%) submitted more than one sample for 
repeated testing. Only 2% of these repeats tested positive after having 
an initial negative result for the C. difficile toxin EIA test. Most recent 
published practice guidelines recommend a two-step or three-step 
testing algorithm in the diagnosis of C. difficile-associated diarrhoea, 
which offers a marked increase in sensitivity when compared to that 
of toxin A and B EIA alone. A three-step protocol is proposed which 
should enable the discernment of the role of C. difficile in a diarrhoeal 
patient.
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immunoassay, algorithm
1 Introduction
Clostridium difficile (C. difficile) is a Gram-positive, spore-forming 
bacterium, spread by the faecal-oral route, which is an important cause 
of nosocomial diarrhoea in industrialised countries. The bacterium 
is non-invasive and only toxigenic strains cause disease, due to the 
production of toxins A and/or B. Carriage occurs in 5-15% of healthy 
adults, but may be as high as 88.4% in newborns and healthy infants, 
and up to 57.0% in residents of long-term care facilities (Surawicz et 
al., 2013).
C. difficile very rarely causes spontaneous disease in healthy young 
individuals. However, antibiotics may disrupt the normal flora of the 
gut, leading to C. difficile overgrowth and, subsequently, C. difficile–
associated diarrhoea. The latter can be complicated by pseudo-
membranous colitis, megacolon, perforation of the colon and possibly 
death. Clinical disease as a result of C. difficile is described as C. difficile 
infection (CDI). The diagnosis of CDI is usually based on the clinical 
history of the patient in combination with laboratory tests.
For the past 30 years, the two primary reference tests were the C. 
difficile cytotoxin neutralisation assay (CCNA) and the toxigenic culture 
(TC). These two methods are time-consuming and require specific 
laboratory facilities as well as technical expertise. As a result, many 
clinical laboratories have replaced the use of these two methods with 
the enzyme immunoassay (EIA) technique, which is able to detect 
both toxins A and B while being less labour-intensive and more cost-
effective. In addition, it allows for faster turn-around time from the 
receipt of the sample to the issuing of results. This test also has high 
specificity. However, specificity is a test characteristic derived from the 
proportion of true negative results out of the total number of negative 
results produced by the test and is not affected by the prevalence of 
disease in the tested population. Therefore, the high specificity of EIA 
toxin A/B is offset in settings where CDI is uncommon, resulting in a 
low positive predictive value (PPV), whereby persons who test positive 
are less likely to truly have the disease. The sensitivity of the toxin EIA 
method is 79-80%, due to low reproducibility compared to the cytotoxin 
assay (She, Durrant & Petti, 2009). These factors undermine the 
confidence clinicians have in tests for CDI detection, thus prompting 
them to order multiple samples per patient.
The practice guidelines published by the Society for Healthcare 
Epidemiology of America (SHEA) in 1995 (cited in Gerding et al., 
1995) state that when C. difficile is clinically suspected, a single stool 
specimen should initially be sent for testing. If the result of this first 
test is negative, one to two additional stool samples should be sent 
for re-testing. Thus, up to three serial toxin EIA tests increase the 
diagnostic yield by as much as 8–10% if the initial test is negative 
(Deshpande et al., 2010). In view of this limited increase in diagnostic 
yield provided by repeat testing, the 2010 SHEA position paper 
suggested that repeat testing during the same episode of diarrhoea is 
of limited value and should be discouraged (Cohen et al., 2010). Tests 
of cure following a positive C. difficile result are not recommended. C. 
difficile toxin positive patients do not need to be retested for C. difficile 
toxin if still symptomatic within a period of 28 days unless symptoms 
resolve and then recur, pointing towards a need to confirm recurrent 
CDI (Department of Health and Health Protection Agency, 2008).
In a study carried out in 2008 by Aichinger et al. (2008), of 683 
patients who had three or more repeat EIA tests performed within 
seven days, 605 (88.6%) had only negative results. Twenty patients 
(2.9%) had a negative result on the first test with subsequent positive 
results on the following tests. In 12 patients, a positive result was 
obtained by the second test, in three patients by the third test, in four 
by the fourth test and in one by the sixth test. The remaining 58 (8.5%) 
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patients had a positive test followed by subsequent positive or negative 
tests (Aichinger et al., 2008). In a study by Nemat et al. (2009), out 
of 1165 positive cases, 1046 (89.8%) tested positive in the first test, 95 
(8.2%) in the second, and only 24 (2.0%) tested positive in the third test. 
In the same study, a second test was ordered after an initial negative 
result in 1,934 cases, of which 95 (4.9%) tested positive, while in 793 
episodes, a third test was ordered after two negative samples, of which 
only 24 (3.0%) resulted in toxin detection. These results highlight the 
ineffectiveness of repeat testing of stools for C. difficile toxin using EIA.
This study was carried out to assess the clinical value of the C. 
difficile toxin EIA technique, by determining the number of cases that 
had repeat stool tests performed during the same diarrhoeal episode, 
with a first negative stool toxin EIA result followed by a positive result. 
The study aimed to ascertain the diagnostic value of these repeat stool 
tests.
2 Methods
A retrospective study was carried out at the state general hospital in 
Malta, which is also a teaching hospital that covers the specialties 
of general medicine and surgery, geriatrics, paediatrics, nephrology, 
transplant, oncology and critical care. Permission to carry out the study 
was granted by the Chairman of the hospital’s Pathology Department. 
The readily available and anonymous data was collected via a 
computer search using the laboratory information system. All requests 
for C. difficile toxin testing between 1st July 2013 and 1st July 2014 were 
included in the study.
All faecal samples submitted for routine testing for C. difficile were 
processed using RIDASCREEN® Clostridium difficile Toxin A/B 
(Product C0801; R-Biopharm AG, Darmstadt, Germany). Sequential 
samples collected during the same diarrhoeal episode and received at 
the laboratory within seven days of an initial negative test result were 
considered repeats. In addition, samples submitted for re-testing after 
an initial positive result within a 28-day time frame were also assessed 
and included in the study.
3 Results
During the study period (1st July 2013 – 1st July 2014), the laboratory 
received 2,489 requests for testing stool samples for C. difficile toxins. 
These had been collected from a total of 1,689 patients. Some patients 
suffered more than one episode of diarrhoea. Upon grouping the 
requests submitted by patient and by date of submission, a total of 
2,053 episodes of diarrhoea were identified. In 1,751 of these diarrhoeal 
episodes, only one sample was collected, from which 23 (1.3%) samples 
yielded a positive result (see Figure 1). There were 302 diarrhoeal 
episodes that were repeatedly tested, which resulted in the submission 
of 738 samples; the mode of the number of samples submitted per 
diarrhoeal episode was 2. From these 302 diarrhoeal episodes, only 6 
(2.0%) had a negative result on the first test, with subsequent positive 
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Figure 1. C. difficile stool testing outcome grouped according to number of samples sent per diarrhoeal episode
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Figure 2. Proposed algorithm to diagnose C. difficile infection
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results on a following test during the same episode. There were a total 
of 28 episodes in which the initial test resulted positive and repeat tests 
for toxin EIA were requested within a period of 28 days after the first 
positive result. In 11 of these episodes, the repeat test was requested 
within seven days of the first test.
4 Discussion
Across Europe, a daily average of 109 patients with CDI are undiagnosed 
due to lack of clinical suspicion or sub-optimal testing. This amounts 
to more than 39,000 cases which are potentially missed each year 
(Davies, Davis & Ashwin, 2014). Missed or imprecise diagnosis has 
implications for infection control practice and patient management.
The diagnosis of CDI is usually based on the clinical history in 
combination with laboratory tests. Various laboratory tests are currently 
available for the detection of C. difficile or its toxins. The diagnostic 
tests for C. difficile can be divided into (i) tests for C. difficile products 
(glutamate dehydrogenase (GDH), aromatic fatty acids, toxins A and/or 
B), (ii) culture methods for the detection of toxin-producing C. difficile 
(toxigenic culture), and (iii) tests for C. difficile genes polymerase chain 
reactions (PCR) for 16S ribonucleic acid (RNA), toxin genes, genes for 
GDH (Crobach et al., 2009).
Practice guidelines for the best testing strategy to diagnose C. 
difficile infection in a clinical laboratory suggest that C. difficile toxin 
EIAs are not suitable as standalone tests for the diagnosis of CDI in 
an endemic situation, due to the low prevalence rate that gives rise 
to low positive predictive values of diagnostic tests (Crobach et al., 
2009). Various authors recommend a two-step method, whereby an 
initial highly sensitive and rapid screening test presumably detects 
all positive cases and is followed up by a second assay that identifies 
the true positive samples amongst all of the positive results detected 
during the screening test (Cohen et al., 2010; Crobach et al., 2009; De 
Silva, 2012; Surawicz et al., 2013).
The enzyme GDH is produced by all Clostridium species, including 
toxigenic and non-toxigenic strains of C. difficile, making it a good 
marker for the presence of C. difficile in stools. This is the basis for rapid 
detection methods using EIA. The negative predictive value (NPV) of 
the GDH test is comparable among populations having different C. 
difficile prevalence, thus making it a potential candidate for inclusion 
in a diagnostic algorithm for CDI (Crobach et al., 2009). A negative 
result would reliably exclude the presence of the organism in faeces. A 
positive GDH test has a very strong concordance with a positive culture 
but is not indicative of toxin production (Shetty et al., 2011). Positive 
GDH EIA requires further confirmatory testing as C. difficile infection 
is a toxin-mediated disease (De Silva, 2012).
Real-time PCR (RT-PCR) is unsuitable as a standalone test, as the 
lower 95% confidence interval for sensitivity is roughly 80–85% and that 
for specificity is about 93% (Planche & Wilcox, 2011). In settings of low 
prevalence, like in an endemic situation where the prevalence of CDI is 
expected to range between 5 and 10%, the PPV would be unacceptably 
low (Crobach et al., 2009). Thus, a highly specific test like RT-PCR 
in settings of low prevalence would lead to a high rate of false positive 
results. A false positive diagnosis could lead to the management and 
treatment of non-infected patients alongside true positive cases which, 
in turn, could potentially result in cross-infection of patients, thereby 
increasing the prevalence rate. Unnecessary treatment of CDI could be 
another outcome, potentially including the withdrawal of CDI-inciting 
antimicrobials that may be required to treat a concurrent infection. In 
addition, RT-PCR is significantly more expensive than EIA.
Therefore, an updated testing algorithm to conform to the recent 
guidelines is proposed (Figure 2). The current hospital guideline for 
the management of CDI would be updated to include guidance on 
test request submission, sample collection and result interpretation 
to complement the new testing algorithm, while discouraging repeat 
testing to ensure an efficient utilisation of laboratory resources. This 
approach must be accompanied by training to increase awareness of 
CDI, especially in view of recent insights into CDI epidemiology.
A number of limitations were present in this study. The type of stool 
sample submitted for testing was not recorded. Ideally, testing should 
be performed only on liquid specimens, thereby excluding testing on 
formed stool samples. Unfortunately, the number of tests carried out on 
formed stool samples is unknown. Moreover, data regarding the number 
of repeat stool tests performed until a positive test result was obtained 
following an initial negative result was not recorded. In addition, the 
time interval between the first negative test result and subsequent 
positive results was not documented.
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